Market Chameleon (Fri, 27-Feb 4:21 AM ET)
Globe Newswire (Fri, 27-Feb 6:50 AM ET)
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 24-Feb 6:50 AM ET)
Globe Newswire (Fri, 13-Feb 6:50 AM ET)
Market Chameleon (Mon, 12-Jan 2:53 AM ET)
Globe Newswire (Mon, 12-Jan 6:50 AM ET)
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 6-Jan 4:15 PM ET)
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Ani Pharmaceuticals trades on the NASDAQ stock market under the symbol ANIP.
As of April 1, 2026, ANIP stock price declined to $75.96 with 375,637 million shares trading.
ANIP has a beta of 0.40, meaning it tends to be less sensitive to market movements. ANIP has a correlation of 0.03 to the broad based SPY ETF.
ANIP has a market cap of $1.71 billion. This is considered a Small Cap stock.
Last quarter Ani Pharmaceuticals reported $247 million in Revenue and $2.33 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.50.
In the last 3 years, ANIP traded as high as $99.50 and as low as $36.99.
The top ETF exchange traded funds that ANIP belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
ANIP has underperformed the market in the last year with a return of +13.5%, while the SPY ETF gained +18.5%. In the last 3 month period, ANIP fell short of the market, returning -3.8%, while SPY returned -3.6%. However, in the most recent 2 weeks ANIP has outperformed the stock market by returning +2.3%, while SPY returned -2.1%.
ANIP support price is $75.21 and resistance is $78.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIP shares will trade within this expected range on the day.
